Clinical Trial Update: Antidiabetic Drugs for Steatotic Liver Disease [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating antidiabetic drugs for steatotic liver disease (MASLD) and type 2 diabetes; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Dysfunction-associated Steatotic Liver Disease
• Non-alcoholic Fatty Liver Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Empagliflozin (empagliflozin)
• PIOGLITAZONE (Pioglitazone)

Snippet

Sponsor: Yonsei University | Conditions: MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Type 2 Diabetes | Phase 4 | Status: COMPLETED